Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of LEM-S401 in Healthy Adults
NCT04707131Phase 1Completed
- Sponsor
- Lemonex Inc.
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Hypertrophic Scar (HS) and keloid comparing LEM-S401 with Placebo (2 arms). Primary endpoint: Incidence of adverse events up to 16 days. Started Jul 2022; status: completed.
02
Drugs
LEM-S401
03
Conditions
Hypertrophic Scar (HS)keloid
Beyond the preview
Go deeper on NCT04707131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707131.